Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1B | Q00975 | 10/20 | 0.53 |
| ▸ | ADRA1D | P25100 | 6/20 | 0.41 |
| ▸ | ADRA1A | P35348 | 6/20 | 0.41 |
| ▸ | ADRA1B | P35368 | 6/20 | 0.41 |
| ▸ | ADRA2A | P08913 | 5/20 | 0.41 |
| ▸ | ADRA2B | P18089 | 5/20 | 0.41 |
| ▸ | ADRA2C | P18825 | 5/20 | 0.41 |
| ▸ | CACNA1F | O60840 | 2/20 | 0.39 |
| ▸ | CACNA1D | Q01668 | 2/20 | 0.39 |
| ▸ | CACNA1S | Q13698 | 2/20 | 0.39 |
| ▸ | CACNA1C | Q13936 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6925859 | 0.89 | CACNA1B (0.51) | CACNA1BADRA1DADRA1AADRA1BADRA2A | |
| SCHEMBL6929492 | 0.89 | CACNA1B (0.55) | CACNA1B | |
| SCHEMBL7526009 | 0.88 | CACNA1B (0.68) | CACNA1BCACNA1FCACNA1DCACNA1SCACNA1C | |
| SCHEMBL7525757 | 0.88 | CACNA1B (0.68) | CACNA1BCACNA1FCACNA1DCACNA1SCACNA1C | |
| SCHEMBL4502482 | 0.88 | CACNA1B (0.59) | CACNA1BADRA1DADRA1AADRA1BADRA2A | |
| SCHEMBL4510068 | 0.88 | CACNA1B (0.59) | CACNA1B | |
| SCHEMBL7532435 | 0.87 | CACNA1B (0.69) | CACNA1BCACNA1FCACNA1DCACNA1SCACNA1C | |
| SCHEMBL7521864 | 0.87 | CACNA1B (0.68) | CACNA1BCACNA1FCACNA1DCACNA1SCACNA1C | |
| SCHEMBL6931116 | 0.86 | CACNA1B (0.58) | CACNA1B | |
| SCHEMBL7527429 | 0.86 | CACNA1B (0.69) | CACNA1BCACNA1FCACNA1DCACNA1SCACNA1C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6610717-B2 | Selectively inhibits action of N-type calcium channel; treatment of ischemic cerebrovascular disorders caused by cerebral infarction or intracerebral bleeding, Alzheimer's disease, AIDS related dementia, Parkinson's disease | AJINOMOTO CO., INC. (JP) | 2003-08-26 | — | — | US | disclosed |
| US-6610717-B2 | Selectively inhibits action of N-type calcium channel; treatment of ischemic cerebrovascular disorders caused by cerebral infarction or intracerebral bleeding, Alzheimer's disease, AIDS related dementia, Parkinson's disease | AJINOMOTO CO., INC. (JP) | 2003-08-26 | — | — | US | disclosed |
| US-6610717-B2 | Selectively inhibits action of N-type calcium channel; treatment of ischemic cerebrovascular disorders caused by cerebral infarction or intracerebral bleeding, Alzheimer's disease, AIDS related dementia, Parkinson's disease | AJINOMOTO CO., INC. (JP) | 2003-08-26 | — | — | US | disclosed |
| US-20020193605-A1 | New dihydropyridine derivatives | AJINOMOTO CO. INC (JP) | 2002-12-19 | — | — | US | disclosed |
| EP-1191022-A1 | NOVEL DIHYDROPYRIDINE DERIVATIVE | Ajinomoto Co., Inc. (JP) | 2002-03-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020193605-A1 | New dihydropyridine derivatives | CACNA1B, CACNA1D, CACNA1C | CACNA1B 1/4885ADRA1D 221/4885ADRA1A 390/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.